The drug was initially given a NICE nod back in 2016, and cleared by the European regulators back in 2011.
News
Social media used to boost cancer screening rates
In an initial pilot that used Facebook to promote breast screening, one area saw a 12.9% increase in the take up of screening services.
Gilead, Glympse Bio to explore biomarker use in NASH
NASH is a chronic and progressive liver disease characterised by fat accumulation and inflammation in the liver, which can lead to scarring, or fibrosis, that impairs liver function.
Sense Biodetection raises £12.3m for molecular diagnostics
The company will use it to develop its portfolio of instrument-free, point-of-care molecular diagnostic tests.
EU ‘yes’ for Bavencio
The approval was based on positive interim results from the Phase III JAVELIN Renal 101 study.
GSK initiates experimental gepotidacin trial
The drug is the first in a new chemical class of antibiotics dubbed “triazaacenaphthylene bacterial topoisomerase inhibitors.”
Late-stage success for Imfinzi in NSCLC
The AstraZeneca human monoclonal antibody binds to PD-L1 and blocks the interaction of PD-L1 with PD-1 and CD80, countering a tumour’s immune-evading tactics.
Finalists announced for Marketer of the Year 2019
The finalists for the 2019 Marketer of the Year competition have now done all they can in their bid to be crowned the winner.
Number of NIHR-supported research participants exceeds 1M
The news marks a “significant milestone.”
NIHR, MRC buddy up to tackle global chronic disease
The organisations announced plans to invest over £6 million in five implementation science projects focused on tackling diabetes and hypertension in low- and middle-income countries.
AZ commits £28m to tackle non-communicable disease
The plan is designed to inform adolescents in under-resourced communities on how to reduce risky behaviours including smoking, alcohol, poor diet and lack of exercise.
Tecentriq, Avastin combo trumps Nexavar in liver cancer
Hepatocellular carcinoma is a major cause of cancer deaths worldwide, affecting over 750,000 people every year.
Gov’t announces social prescribing academy updates
Only 60% of CCGs use social prescribing for patients with anxiety, mental health problems and dementia, despite evidence that it helps.
Investigational gene therapy shows long-term success in AADC
There are currently no approved therapies that address the underlying cause of aromatic L-amino acid decarboxylase (AADC) deficiency.
‘Revolutionary’ liquid sickle cell treatment unveiled
The new formation will enable doctors to personalise doses for young children.
